Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 9/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 4/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | CASP1 | P29466 | 2/20 | 0.38 |
| ▸ | CASP7 | P55210 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1699245 | 0.93 | OPRD1 (0.45) | OPRD1KCNH2PDE10APDE4BUSP2 | |
| SCHEMBL9981160 | 0.82 | PDE10A (0.43) | PDE10AHTTPDE4BDRD1DRD5 | |
| SCHEMBL1701334 | 0.82 | PDE10A (0.47) | PDE10AHTTPDE4BCYP1A2CYP3A4 | |
| SCHEMBL9981615 | 0.82 | PDE10A (0.44) | PDE10AHTTPDE4B | |
| SCHEMBL9981385 | 0.81 | PDE10A (0.46) | PDE10AHTTPDE4BHPGD | |
| SCHEMBL15946514 | 0.81 | PDE10A (0.46) | PDE10AHTT | |
| SCHEMBL9981045 | 0.79 | PDE10A (0.44) | PDE10AHTTPDE4B | |
| SCHEMBL15418003 | 0.76 | PDE10A (0.39) | PDE10AHTTPDE4BALDH1A1HPGD | |
| SCHEMBL9981156 | 0.76 | NPC1 (0.48) | OPRD1KCNH2LMNA | |
| SCHEMBL9980990 | 0.75 | PDE10A (0.44) | PDE10AHTTPDE4BLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2585462-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| EP-2585462-B1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2020-02-26 | — | — | EP | disclosed |
| US-9226921-B2 | Fused heterocyclic compounds as phosphodiesterases (PDES) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-01-05 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8940758-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-01-27 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-8846713-B2 | Fused heterocyclic compounds as phosphodiesterases (PDEs) inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-09-30 | — | — | US | disclosed |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-08-14 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-8563575-B2 | Fused heterocyclic compounds | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-10-22 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | CROSSWING INC. (CA) | 2013-07-04 | — | — | US | disclosed |
| WO-2011163355-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | WO | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172328-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | OPRD1 1630/4885KCNH2 932/4885PDE10A 13/4885 |
| US-20110319394-A1 | FUSED HETEROCYCLIC COMPOUNDS | PDE5A, PDE2A, PDE3A | OPRD1 1611/4885KCNH2 1272/4885PDE10A 12/4885 |
| US-20140228320-A1 | FUSED HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASES (PDES) INHIBITORS | PDE3A, PDE5A, PDE2A | OPRD1 1630/4885KCNH2 932/4885PDE10A 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.